Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
1978
|
| gptkbp:contraindication |
hypersensitivity to butorphanol
patients with opioid dependence |
| gptkbp:controlledSubstanceSchedule |
Schedule IV (US)
|
| gptkbp:drugClass |
opioid
|
| gptkbp:eliminationHalfLife |
5-6 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:genericName |
gptkb:butorphanol
|
| https://www.w3.org/2000/01/rdf-schema#label |
Stadol
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:mechanismOfAction |
partial agonist-antagonist at opioid receptors
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
intramuscular
intravenous nasal spray |
| gptkbp:sideEffect |
nausea
dizziness sweating drowsiness sedation |
| gptkbp:status |
FDA approved
|
| gptkbp:usedFor |
pain management
migraine treatment |
| gptkbp:bfsParent |
gptkb:Butorphanol
gptkb:butorphanol |
| gptkbp:bfsLayer |
8
|